Proteome analysis of ventral midbrain in MPTP-treated normal and L1cam transgenic mice

被引:31
作者
Diedrich, Madeleine [2 ]
Mao, Lei [1 ]
Bernreuther, Christian [3 ,4 ]
Zabel, Claus [1 ]
Nebrich, Grit [1 ]
Kleene, Ralf [5 ]
Mosel, Joachim [1 ]
机构
[1] Charite, Inst Humangenet, D-13353 Berlin, Germany
[2] Free Univ Berlin, Fachbereich Biol, Pharmazie, Germany
[3] Inst Biosynthese Neuraler Struckturen, Zentrum Mol Neurobiol, Hamburg, Germany
[4] Univ Med Ctr Hamburg Eppenderof, Inst Neuropathol, Hamburg, Germany
[5] Univ Klinikim Hamburg Eppendorf, Zentrum Mol Neurobiol, Hamburg, Germany
关键词
MPTP; Parkinson disease; transgene;
D O I
10.1002/pmic.200700754
中图分类号
Q5 [生物化学];
学科分类号
071010 ; 081704 ;
摘要
Treatment of mice by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridene hydrochloride (MPTP) is a well established animal model for Parkinson's disease (PD), while overexpression of L1 cell adhesion molecule (L1cam) has been proposed to attenuate the degeneration of dopaminergic neurons induced by MPTP. To gain insight into the role of L1cam in the pathomechanism of PD, we investigated protein expression patterns after MPTP-treatment in both C57BL/6 (wild-type) and transgenic mice overexpressing L1cam in astrocytes. Our results showed that during the acute phase, proteins in functional complexes responsible for mitochondrial, glycolysis, and cytoskeletal function were down-regulated in MPTP-treated wild-type mice. After a recovery phase, proteins that were down-regulated in the acute phase reverted to normal levels. In L1cam. transgenic mice, a much higher number of proteins was altered during the acute phase and this number even increased after the recovery phase. Many proteins involved in oxidative phosphorylation were still down-regulated and glycolysis related protein were still up-regulated. This pattern indicates a lasting severely impaired energy production in L1cam mice after MPTP treatment.
引用
收藏
页码:1266 / 1275
页数:10
相关论文
共 45 条
[1]   Experimental models of Parkinson's disease [J].
Beal, MF .
NATURE REVIEWS NEUROSCIENCE, 2001, 2 (05) :325-332
[2]  
BERETTA L, 1993, J BIOL CHEM, V268, P20076
[3]   The SWISS-PROT protein knowledgebase and its supplement TrEMBL in 2003 [J].
Boeckmann, B ;
Bairoch, A ;
Apweiler, R ;
Blatter, MC ;
Estreicher, A ;
Gasteiger, E ;
Martin, MJ ;
Michoud, K ;
O'Donovan, C ;
Phan, I ;
Pilbout, S ;
Schneider, M .
NUCLEIC ACIDS RESEARCH, 2003, 31 (01) :365-370
[4]   Molecular pathways to neurodegeneration [J].
Bossy-Wetzel, E ;
Schwarzenbacher, R ;
Lipton, SA .
NATURE MEDICINE, 2004, 10 (07) :S2-S9
[5]   Parkinson's disease: Mechanisms and models [J].
Dauer, W ;
Przedborski, S .
NEURON, 2003, 39 (06) :889-909
[6]  
Dawson TM, 2006, J NEURAL TRANSM-SUPP, P209
[7]   Molecular pathways of neurodegeneration in Parkinson's disease [J].
Dawson, TM ;
Dawson, VL .
SCIENCE, 2003, 302 (5646) :819-822
[8]   Parkinson-like syndrome induced by continuous MPTP infusion:: Convergent roles of the ubiquitin-proteasome system and α-synuclein [J].
Fornai, F ;
Schlüter, OM ;
Lenzi, P ;
Gesi, M ;
Ruffoli, R ;
Ferrucci, M ;
Lazzeri, G ;
Busceti, CL ;
Pontarelli, F ;
Battaglia, G ;
Pellegrini, A ;
Nicoletti, F ;
Ruggieri, S ;
Paparelli, A ;
Südhof, TC .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2005, 102 (09) :3413-3418
[9]   Gene expression profiling of parkinsonian substantia nigra pars compacta;: alterations in ubiquitin-proteasome, heat shock protein, iron and oxidative stress regulated proteins, cell adhesion/cellular matrix and vesicle trafficking genes [J].
Grünblatt, E ;
Mandel, S ;
Jacob-Hirsch, J ;
Zeligson, S ;
Amariglo, N ;
Rechavi, G ;
Li, J ;
Ravid, R ;
Roggendorf, W ;
Riederer, P ;
Youdim, MBH .
JOURNAL OF NEURAL TRANSMISSION, 2004, 111 (12) :1543-1573
[10]  
Hulley P, 1998, J NEUROSCI RES, V53, P129, DOI 10.1002/(SICI)1097-4547(19980715)53:2<129::AID-JNR1>3.0.CO